Information Provided By: 
Fly News Breaks for April 6, 2015
BMY, QURE
Apr 6, 2015 | 12:13 EDT
Piper Jaffray raised its price target for uniQure (QURE) to $40 saying the company's deal with Bristol-Myers' (BMY) validates its gene therapy platform and baculovirus manufacturing capabilities. Piper thinks the news also takes some of the pressure off Glybera's launch in Europe and sets up uniQure shares for hemophilia B data in the second half of 2015. It reiterates an Overweight rating on the stock.
News For QURE;BMY From the Last 2 Days
